Literature DB >> 28520854

Declines in Human Papillomavirus (HPV)-Associated High-Grade Cervical Lesions After Introduction of HPV Vaccines in Connecticut, United States, 2008-2015.

Linda M Niccolai1,2, James I Meek1,2, Monica Brackney1,2, James L Hadler1,2, Lynn E Sosa3, Daniel M Weinberger2.   

Abstract

BACKGROUND: Trends in human papillomavirus (HPV)-associated cervical lesions can provide an indication of vaccine impact. Our purpose was to measure trends in cervical lesions during 2008-2015 and to consider possible explanations including vaccination coverage, changes in screening for cervical cancer, and risk behaviors for acquiring HPV.
METHODS: Connecticut (CT) implemented mandatory reporting of cervical intraepithelial neoplasia grades 2/3 and adenocarcinoma in situ (cervical intraepithelial neoplasia grade 2 or higher [CIN2+]) in 2008. Trends by age and birth cohort were modeled using negative binomial regression and change-point methods. To evaluate possible explanations for changes, these trends were compared to changes in HPV vaccination coverage, cervical cancer screening, an antecedent event to detection of a high-grade lesion, and changes in sexual behaviors and Chlamydia trachomatis, an infection with similar epidemiology to and shared risk factors for HPV.
RESULTS: A significant decline in CIN2+ was first evident among women aged 21 years in 2010, followed by successive declines in women aged 22-26 years during 2011-2012. During 2008-2015, the rates of CIN2+ declined by 30%-74% among women aged 21-26 years, with greater declines observed in the younger women. Birth cohorts between 1985 and 1994 all experienced significant declines during the surveillance period, ranging from 25% to 82%. Ecological comparisons revealed substantial increases in HPV vaccination during this time period, and more modest reductions in cervical cancer screening and sexual risk behaviors.
CONCLUSIONS: The age and cohort patterns in our data suggest that declines in CIN2+ during 2008-2015 are more likely driven by HPV vaccination, introduced in 2006, than by changes in screening or risk behavior.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com

Entities:  

Keywords:  cervical lesions; human papillomavirus; surveillance; vaccination; vaccine impact

Mesh:

Substances:

Year:  2017        PMID: 28520854     DOI: 10.1093/cid/cix455

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  12 in total

1.  Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study.

Authors:  Michael J Silverberg; Wendy A Leyden; Jennifer O Lam; Steven E Gregorich; Megan J Huchko; Shalini Kulasingam; Miriam Kuppermann; Karen K Smith-McCune; George F Sawaya
Journal:  Lancet Child Adolesc Health       Date:  2018-08-08

2.  Assessing sociodemographic differences in human papillomavirus vaccine impact studies in the United States: a systematic review using narrative synthesis.

Authors:  L R Avni-Singer; A Yakely; S S Sheth; E D Shapiro; L M Niccolai; C R Oliveira
Journal:  Public Health       Date:  2019-11-04       Impact factor: 2.427

3.  Trends in Human Papillomavirus Vaccine Types 16 and 18 in Cervical Precancers, 2008-2014.

Authors:  Nancy M McClung; Julia W Gargano; Nancy M Bennett; Linda M Niccolai; Nasreen Abdullah; Marie R Griffin; Ina U Park; Angela A Cleveland; Troy D Querec; Elizabeth R Unger; Lauri E Markowitz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-02-21       Impact factor: 4.254

4.  Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.

Authors:  Mélanie Drolet; Élodie Bénard; Norma Pérez; Marc Brisson
Journal:  Lancet       Date:  2019-06-26       Impact factor: 79.321

5.  Trends in Precancerous Cervical Lesions by Area-Based Measures of Poverty, Race, and Ethnicity, Connecticut, 2008-2018.

Authors:  Monica M Brackney; Daniel M Weinberger; Kyle Higgins; James Meek; Linda M Niccolai
Journal:  Public Health Rep       Date:  2021-11-02       Impact factor: 3.117

6.  Evaluation of an Inpatient Postpartum Human Papillomavirus Immunization Program.

Authors:  Lital Avni-Singer; Carlos R Oliveira; Ashlynn Torres; Eugene D Shapiro; Linda M Niccolai; Sangini S Sheth
Journal:  Obstet Gynecol       Date:  2020-11       Impact factor: 7.623

7.  Changes in Cervical Human Papillomavirus (HPV) Prevalence at a Youth Clinic in Stockholm, Sweden, a Decade After the Introduction of the HPV Vaccine.

Authors:  Andreas Ährlund-Richter; Liqin Cheng; Yue O O Hu; Mikaela Svensson; Alexandra A L Pennhag; Ramona G Ursu; Linnea Haeggblom; Nathalie Grün; Torbjörn Ramqvist; Lars Engstrand; Tina Dalianis; Juan Du
Journal:  Front Cell Infect Microbiol       Date:  2019-03-20       Impact factor: 5.293

8.  Reduction in hospitalisations for acute gastroenteritis-associated childhood seizures since introduction of rotavirus vaccination: a time-series and change-point analysis of hospital admissions in England.

Authors:  Daniel James Hungerford; Neil French; Miren Iturriza-Gómara; Jonathan M Read; Nigel A Cunliffe; Roberto Vivancos
Journal:  J Epidemiol Community Health       Date:  2019-09-11       Impact factor: 3.710

9.  Monitoring HPV vaccine impact on cervical disease: Status and future directions for the era of cervical cancer elimination.

Authors:  Carlos R Oliveira; Linda M Niccolai
Journal:  Prev Med       Date:  2021-03-04       Impact factor: 4.018

10.  Human Papillomavirus Vaccination in Male and Female Adolescents Before and After Kidney Transplantation: A Pediatric Nephrology Research Consortium Study.

Authors:  Corina Nailescu; Raoul D Nelson; Priya S Verghese; Katherine E Twombley; Aftab S Chishti; Michele Mills; John D Mahan; James E Slaven; Marcia L Shew
Journal:  Front Pediatr       Date:  2020-02-20       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.